Bristol-Myers Squibb 10-Kyear ended 2025-12-31

Executive Summary

Bristol Myers Squibb’s FY2025 revenue was essentially flat, but its business mix shifted: newer medicines grew rapidly enough to offset much of the decline in products facing generic competition. GAAP earnings rebounded chiefly because acquisition-related research and intangible charges fell from unusually high FY2024 levels, not because sales accelerated. Operating cash flow funded dividends and debt reduction while the company invested in partnerships, acquisitions and specialized manufacturing. For investors, the central test is whether the Growth Portfolio and pipeline can replace legacy sales and expiring royalties as U.S. pricing pressure intensifies.

Key Financial Highlights

• Earnings quality: Acquired in-process research and development expense fell to $3.72B from $13.4B, and acquired-intangible amortization fell to $3.32B from $8.87B. Amortization and other noncash charges help explain why OCF exceeded net earnings; OCF nevertheless declined as rebate payments rose.
• Pricing realization: Gross product sales increased 5% to $88.1B, but gross-to-net deductions rose 12% to $41.3B, absorbing the increase and leaving net product sales nearly flat. U.S. deductions reached 53% of gross product sales, up from 49%.
• Capital allocation: Dividends paid were $5.05B, with no share repurchases; stock-based compensation was $553M. Diluted weighted-average shares rose to 2.04B from 2.03B. BMS issued €5.0B principal of notes and repurchased or redeemed $8.7B principal of debt; interest payments rose to $2.1B.
• Balance-sheet exposure: Goodwill was $21.8B and other intangible assets were $19.1B. FY2025 intangible impairments of $949M show the sensitivity of acquired asset values to revised commercial and development expectations.

Business Developments

Eliquis and Opdivo grew 8% each, to $14.4B and $10.0B, while Reblozyl, Breyanzi and Camzyos grew 31%, 82% and 77%, respectively. Those gains countered steep declines in Revlimid, Pomalyst/Imnovid and Sprycel. Management is directing investment toward oncology, cell therapy, radiopharmaceuticals, immunology and neuroscience; the inferred consequence is greater dependence on launches and new indications to replace mature-product revenue.

BMS acquired Orbital Therapeutics and partnered with BioNTech on pumitamig, paying $1.5B upfront for that collaboration. It also expanded specialized cell-therapy and radiopharmaceutical manufacturing capacity. Pipeline progress was mixed: Sotyktu’s Phase III psoriatic-arthritis studies met their primary endpoints, while trials involving milvexian, Cobenfy and other products encountered setbacks. A productivity initiative targets $2.0B of savings by the end of 2027, creating room for investment but not eliminating development risk.

A December 2025 U.S. Government Agreement commits BMS to provide Eliquis free to Medicaid beginning 1/1/2026 and to offer selected medicines to cash-paying patients at discounts of ≈80% from current list prices. In exchange, BMS receives certain tariff relief through January 2029 and an exemption from future U.S. pricing mandates. The arrangement changes access and pricing economics even as it limits specified policy exposures.

Risk Assessment

• Exclusivity and concentration: Eliquis and Opdivo generated $24.5B combined; expanding Eliquis generic competition, unlimited-volume U.S. generic Revlimid licenses from 1/31/2026 and expected Pomalyst generic entry threaten replacement sales.
• Pricing and reimbursement: Eliquis Medicare negotiated pricing begins 1/1/2026, followed by Pomalyst in 2027 and Orencia in 2028; rising rebates can prevent gross-sales growth from reaching net revenue.
• Pipeline execution: Clinical failures, approval delays, manufacturing scale-up and reimbursement barriers could leave Growth Portfolio launches insufficient to offset legacy declines and could trigger further impairments.
• Royalties: Royalty-related pretax income was ≈$2.7B; the diabetes-business stream ended in 2025, and Keytruda and Tecentriq royalties are expected to end on 12/31/2026.
• Leverage and acquired assets: Short-term debt was $2.26B and long-term debt $42.9B; financing costs and acquisition-related asset write-downs could constrain future investment and returns.
• Operations and cybersecurity: Complex cell-therapy and radiopharmaceutical supply chains, third-party dependence and cyberattacks could disrupt production or expose sensitive information, despite BMS reporting no known material cyber incident in the prior three years.
• Customer and estimate concentration: Three U.S. wholesalers represented 87% of U.S. gross product sales, while rebate accruals and transfer-pricing tax liabilities require substantial judgment and could affect period results.

Strategic Outlook and Investor Actionables

BMS enters 2026 with growing newer brands and lower net debt, but also a sharper need to overcome generic erosion, negotiated pricing and the loss of royalty income. The investment case strengthens if new-product adoption converts pipeline spending into durable net sales rather than further charges.

• Portfolio replacement: Track Growth Portfolio gains against Legacy Portfolio declines, particularly after Revlimid and Pomalyst generic expansion.
• Net-price resilience: Track U.S. gross-to-net deductions and Eliquis net sales under Medicare negotiated pricing and the Medicaid agreement.
• Pipeline and cash returns: Track 2026 clinical and regulatory decisions, impairments, OCF and net debt to test whether investment is producing replacement growth without reversing deleveraging.